LONDON, July 11, 2019 /PRNewswire/ — Meril’s recently CE-approved MeRes100, used for the treatment of de-novocoronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years. “First generation bioresorbable scaffolds have not […]
Coronary/Structural Heart
LivaNova Celebrates 25 Years of Vagus Nerve Stimulation Therapy
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, is celebrating the 25th anniversary of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System. This clinically proven, safe and effective therapy is used for the treatment of Drug-Resistant Epilepsy (DRE), Treatment-Resistant Depression (TRD) and for the delivery of Autonomic Regulation Therapy for […]
Corindus Announces First Commercial Installation of CorPath® GRX System in South America
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the […]
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking another important step towards trial completion. Given the remaining steps […]
Quantum Genomics Selected to Enter the European Rising Tech Label
PARIS and NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, has been selected to enter the European Rising Tech […]
FEops HEARTguideTM Wins CSI Highlight of the Year Award
GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that FEops HEARTguideTM was the winning entry at CSI Frankfurt 2019 voted on by physician attendees for the Highlight of the year award in the category interventional imaging. This award celebrates promising technologies that will have the […]
Eko Unveils Algorithm to Assist in the Detection of Aortic Stenosis, a Valvular Heart Disease Affecting Over 3 Million People in the U.S.
Berkeley, June 28, 2019 (GLOBE NEWSWIRE) — Eko, a Berkeley-based digital health company applying artificial intelligence and machine learning in the fight against heart disease, unveiled an investigational Aortic Stenosis (AS) detection algorithm at the American Society of Echocardiography (ASE) 2019 Scientific Sessions aimed to assist healthcare providers in the early detection of […]
Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation
KIRKLAND, Wash., July 1, 2019 /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Carillon Mitral Contour System® has been implanted in 1,000 patients in the United States, Europe, Australia, Turkeyand the Middle East. The Carillon System is a right-heart transcatheter mitral […]
Acarix CADScor®System included in NICE guidelines (UK)
Malmö June 27, 2019 Acarix CADScor®System included in NICE guidelines (UK) Acarix AB (publ) (ACARIX: FN Stockholm) today announced that the CADScor®System has been included as a first line investigation for ruling out suspected stable Coronary Artery Disease by the British National Institute for Health and Care Excellence (NICE). The […]
Neovasc Announces Presentations on Tiara™ for Treatment of Mitral Regurgitation and Reducer™ for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference
VANCOUVER, June 27, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ (“Tiara”) transcatheter mitral valve replacement device […]



